Jefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments Momentum Movers

Repligen (RGEN) PT Lowered to $940 at Truist SecuritiesApril 29, 2025 4:03 PM Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'April 29, 2025 2:54 PM Wolfe Research Upgrades Repligen (RGEN) to OutperformApril 29, 2025 2:20 PM Repligen (RGEN) Tops Q1 EPS by 4c, provides guidanceApril 29, 2025 7:33 AM Form 8-K REPLIGEN CORP For: Apr 29April 29, 2025 7:33 AM Repligen Reports First Quarter 2025 Financial ResultsApril 29, 2025 7:30 AM